Sanofi’s Q3 revenue grew by 12.3% to €13.438 billion, driven by products like Dupixent and influenza vaccines. Dupixent remains a top growth driver, with potential peak sales exceeding $20 ...

Influenza Vaccines Market is estimated to valued at USD 8.30 Bn in 2024 and is expected to reach USD 13.43 Bn by 2031, exhibiting CAGR of 7.1% from 2024-2031 BURLINGAME, CA, UNITED STATES, January ...

While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

“We’re all-in on the U.S.” As for Sanofi, the company commercializes a range of vaccines against influenza, polio, pertussis, Haemophilus influenzae type b-related illness, meningitis and ...

The announcement comes just weeks after Sanofi’s two combination vaccine candidates for COVID-19 and influenza were granted fast track designation by the US Food and Drug Administration for use in ...

influenza. "This merger helped the two companies gain leverage in the market, taking advantage of synergies to cut costs and increase development." On 6 May 2011, Sanofi-Aventis simplified its ...

The WHO is a United Nations agency that aims to expand universal health coverage, coordinates responses to health emergencies ...

Five of these vaccines are being manufactured utilising mRNA technology, including GSK/CureVac’s influenza A/H5N1 vaccine, Moderna’s mRNA-1018, and Sanofi’s influenza H5 vaccine. The US ...

The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat.

The DNA sequence encoding this antigen will be combined into the DNA of the baculovirus expression platform, the basis of Sanofi’s licensed recombinant influenza product. This will be used to ...

The partnership with Sanofi offers significant benefits but ... including its NanoFlu seasonal Flu vaccine that it had been readying for a near term BLA. This has now been dropped from its ...